|Positive WB detected in
|human blood tissue, human plasma tissue
|Positive IHC detected in
|human liver cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)
|WB : 1:500-1:1000
|IHC : 1:20-1:200
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
11819-1-AP targets C4BPA in WB, IHC, ELISA applications and shows reactivity with human samples.
|Host / Isotype
|Rabbit / IgG
|C4BPA fusion protein Ag2387
|complement component 4 binding protein, alpha
|Calculated molecular weight
|597 aa, 67 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
C4b-binding protein (C4BP) is a large oligomeric glycoprotein, present in plasma at a concentration of approximately 200 mg/L (PMID: 24218259). It is the main inhibitor of the classical complement and lectin pathway. C4BP is composed of two polypeptides (alpha and beta chains), which have molecular weights of 70 and 45 kDa, respectively (PMID: 7561113). This polyclonal antibody is raised against the C4BP alpha chain (C4BPA).
Extracellular vesicle biomarkers for complement dysfunction in schizophrenia
Hepatitis B virus X protein up-regulates C4b-binding protein α through activating transcription factor Sp1 in protection of hepatoma cells from complement attack.
The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.
World J Surg Oncol
Proteomic analysis of small extracellular vesicles from the plasma of patients with hepatocellular carcinoma